Publication details
Studie TECOS
| Title in English | The TECOS study |
|---|---|
| Authors | |
| Year of publication | 2015 |
| Type | Article in Periodical |
| Magazine / Source | Hypertenze & kardiovaskulární prevence |
| MU Faculty or unit | |
| Citation | |
| Field | Cardiovascular diseases incl. cardiosurgery |
| Keywords | diabetes melolitut; sitagliptin; heart failure |
| Description | The TECOS study demonstrated in 14 671 that sitagliptin - dipeptilpetidas inhibitor 4 - is an effective and safe drug in patients with diabeters mellitus. The glycosylated haemoglobin decreased by 0,29% and the primary cardiovascular endpoint appeared in 839 (11,4%) patients on sitagliptin and in 851 (11,6%) patients on placebo (p < 0,001). There was no increase in heart failure hospitalisation. |